角膜新生血管的药物治疗

The status and prospect of medical treatment on corneal neovascularization

临床上对角膜新生血管的治疗包括局部滴用糖皮质激素、非甾体类抗炎药物,对新生血管进行电凝、激光光凝、光动力疗法等,但临床效果不甚理想.目前抗血管内皮生长因子药物治疗角膜新生血管已用于临床,包括贝伐单抗、雷珠单抗、VEGF trap、干扰RNA等.多西环素、米诺环素等抗生素被证实对角膜新生血管有抑制作用.免疫抑制剂,如环孢素、雷帕霉素也被用于角膜新生血管的治疗.本文综述了角膜新生血管药物治疗的现状及未来可能的研发方向.

Current treatments for corneal neovascularization,including topical steroids,nonsteroidal inflammatory agents,fine needle diathermy,argon laser photocoagulation,and photodynamic therapy have limited clinical efficacy.Vascular endothelial growth factor （VEGF） is one of the most important mediators of angiogenesis,and anti-VEGF agents,including avastin,lucentis,VEGF trap and siRNA have excellent efficacy for the treatment of corneal neovascularization.Doxycycline,minocycline and other antibiotics are also confirmed to have inhibitory effect on corneal neovascularization.Immunosuppressive drugs,such as cyclosporine and rapamycin have also been used in the treatment of corneal neovascularization.This paper reviewed the current situation and prospect of medical treatment on corneal neovascularization.